Compare Applied Materials, Inc. (AMAT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Materials, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Applied Materials, Inc. trades at $581.85 (market cap $478.36B), while Vertex Pharmaceuticals Incorporated trades at $486.42 (market cap $123.19B). The key difference: Applied Materials, Inc. is far larger — about 3.9× Vertex Pharmaceuticals Incorporated's market cap, and Applied Materials, Inc. pays a 0.35% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AMAT | VRTX | |
|---|---|---|
Market Cap | $478.36B | $123.19B |
Sector | Technology | Health |
52-Week High | $723.00 | $529.59 |
52-Week Low | $156.25 | $366.54 |
Enterprise Value | $477.39B | $117.93B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Materials (AMAT) trades at $602.50, up 2.35% today, with strong earnings beats in recent quarters and a consensus analyst price target of $644.33. The stock shows a bullish moving average signal but neutral oscillators, with key resistance at $617 and support at $573. Revenue grew to $28.37B in 2025, with a net income margin of 24.66%, though valuation ratios like P/E of 56.68 are elevated. Recent news highlights CEO Gary Dickerson's optimism on AI-driven semiconductor demand, positioning AMAT for multi-year growth.
The outlook for AMAT is positive, driven by AI infrastructure expansion and consistent earnings outperformance. Risks include high valuation multiples and semiconductor cycle volatility. With 76.9% of analysts rating it a buy and institutional sentiment bullish, the stock offers growth potential but requires monitoring of execution and market conditions.
Vertex Pharmaceuticals (VRTX) trades at $485.39, down 2.24% today but maintains a bullish technical trend with strong support at $486. The company reported robust 2025 results with $12.00B revenue and $3.95B net income, though margins dipped slightly. Recent news highlights a strategic $10B acquisition of Crinetics Pharmaceuticals, expanding its endocrinology portfolio with potential $5B peak sales. Analyst consensus remains strongly bullish with an 83.9% buy rating and $526.50 price target.
Outlook is positive driven by earnings growth and strategic acquisitions, but risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. The stock offers upside to consensus targets but faces volatility near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
